Arphamid Therapeutics GmbH
Adjuvant neuro-endocrine therapy to change how opioids work
We are pioneering the development of small-molecule drugs targeting neuroendocrine G-protein-coupled receptors to address significant unmet medical needs that emerge during chronic opioid treatment.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
02.10.2023
Signed option agreement GPR103 antagonists with the Univ of Strasbourg / SATT Conectus
No Jobs
No videos and documents
No Awards
Arphamid Therapeutics GmbH
Adjuvant neuro-endocrine therapy to change how opioids work
Acquired by:
Novaremed
Novaremed
Headquarter:
Basel
Foundation Date:
September 2023
Technology:
- Biotech
Sectors:
- Biotech
- Neurology
- Small molecule drugs